Repare Therapeutics (NASDAQ:RPTX) Earns “Buy” Rating from HC Wainwright

HC Wainwright reissued their buy rating on shares of Repare Therapeutics (NASDAQ:RPTX) in a report released on Friday morning,Benzinga reports. The brokerage currently has a $10.00 price objective on the stock.

Separately, Lifesci Capital upgraded Repare Therapeutics to a “strong-buy” rating in a research report on Monday, July 29th.

Repare Therapeutics Stock Up 3.1 %

NASDAQ RPTX opened at $3.70 on Friday. The firm has a market cap of $157.07 million, a P/E ratio of -1.85 and a beta of 0.72. The company’s 50 day moving average is $3.37 and its 200-day moving average is $3.40. Repare Therapeutics has a 12-month low of $2.71 and a 12-month high of $8.49.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in RPTX. Acadian Asset Management LLC lifted its holdings in shares of Repare Therapeutics by 212.1% during the 2nd quarter. Acadian Asset Management LLC now owns 417,929 shares of the company’s stock worth $1,373,000 after acquiring an additional 284,036 shares during the last quarter. Blue Owl Capital Holdings LP raised its holdings in shares of Repare Therapeutics by 8.0% during the 2nd quarter. Blue Owl Capital Holdings LP now owns 3,372,499 shares of the company’s stock valued at $11,129,000 after buying an additional 250,000 shares in the last quarter. XTX Topco Ltd bought a new stake in Repare Therapeutics in the 2nd quarter worth approximately $110,000. Marshall Wace LLP bought a new position in Repare Therapeutics during the second quarter valued at approximately $273,000. Finally, Vontobel Holding Ltd. raised its stake in shares of Repare Therapeutics by 20.0% during the third quarter. Vontobel Holding Ltd. now owns 24,000 shares of the company’s stock worth $83,000 after acquiring an additional 4,000 shares in the last quarter. 85.09% of the stock is currently owned by hedge funds and other institutional investors.

About Repare Therapeutics

Repare Therapeutics Inc, a clinical-stage precision oncology company, engages in the discovery and development of therapeutics by using its synthetic lethality approach in Canada and the United States. It uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform, to discover, validate, and build a pipeline of SL-based therapeutics that focuses on genomic instability, including DNA damage repair.